TheraRadar
← Back
Data updated: May 24, 2026

GLENMARK PHARMS

Generics

GLENMARK PHARMS is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.

2005
Since
145
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
2 Small Molecules

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 37%
13 drugs
Neurology 23%
8 drugs
Dermatology 17%
6 drugs
Oncology 14%
5 drugs
Infectious Disease 9%
3 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • EZETIMIBE AND SIMVASTATIN leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling